Olaparib in treatment of men with mCRPC and selected HRR gene mutations

Posted on April 27, 2020 by Sitemaster

According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … overall survival (OS)” in men with metastatic, castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM gene mutations (homologous repair gene mutations or HRRm). … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , , | 11 Comments »

FDA approves new technique for “ablation of prostate tissue”

Posted on August 21, 2019 by Sitemaster

According to a media release issued by a Canadian company called Profound Medical on August 16, the US Food and Drug Administration (FDA) has approved the use of a system called TULSA-PRO for the “ablation of prostate tissue”. There appears to be no relevant information on the FDA web site — as yet. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , , | 8 Comments »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives